Inactive Instrument

Can-Fite BioPharma Ltd. TEL AVIV STOCK EXCHANGE

CANF

IL0010944739

Can-Fite BioPharma Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022

November 25, 2022 at 07:00 am EST

Can-Fite BioPharma Ltd. reported earnings results for the nine months ended September 30, 2022. For the nine months, the company reported sales was USD 0.613 million compared to USD 0.649 million a year ago. Net loss was USD 7.15 million compared to USD 8.5 million a year ago.

Basic loss per share from continuing operations was USD 0.01 compared to USD 0.02 a year ago.

Latest news about Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. Receives Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602	May. 06	CI
Can-Fite Biopharma Ltd. Announces Submission of an Investigational New Drug Application to the U.S. Food and Drug Administration for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis, Also Known as Non-Alcoholic Steatohepatitis, for the Company's Ongoing Phase IIb Clinical Study	Apr. 03	CI
Can-Fite Biopharma Ltd. Announces Clinical Update	Mar. 28	CI
Can-Fite BioPharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Can-Fite Biopharma Ltd. to Present Data from the Pancreatic and Liver Cancer Programs	Mar. 11	CI
Can-Fite BioPharma Ltd. Receives Notice of Allowance from the Canadian Intellectual Property Office	Feb. 28	CI
Can-Fite BioPharma Ltd. Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication	Jan. 30	CI
Can-Fite Biopharma Ltd. Announces Results from Randomized Phase 3 Clinical Trial	Jan. 29	CI
Can-Fite BioPharma Ltd. Reports New Data on Namodenoson?s Anti-Obesity Mechanism of Action	Dec. 20	CI
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan	Dec. 18	RE
Can-Fite BioPharma Ltd. Receives Positive Response from U.S. Food and Drug Administration on Pediatric Study Plan for Treatment of Children Suffering from Psoriasis with Piclidenoson	Dec. 18	CI
Can-Fite BioPharma Ltd. Completes the Design of a Phase IIa Study Protocol for the Treatment of Pancreatic Cancer Patients	Dec. 04	CI
Can-Fite BioPharma Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	Nov. 30	CI
Sector Update: Health Care Stocks Higher Late Tuesday Afternoon	Nov. 21	MT
Top Midday Gainers	Nov. 21	MT
Can-Fite Biopharma Reports 'Complete Response' in Liver Cancer Patient Treated With Namodenoson	Nov. 21	MT
Top Premarket Gainers	Nov. 21	MT
Can-Fite Biopharma Ltd. Announces Complete Response and 6.9 Years Overall Survival in A Patient with Advanced Liver Cancer Treated with Namodenoson	Nov. 21	CI
Can-Fite Biopharma Ltd. Provides Business Update	Nov. 01	CI
Can-Fite Biopharma Ltd. Announces Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal	23-10-30	CI
Can-Fite Biopharma Ltd. Enters into an Agreement with Collaborations Pharmaceuticals Inc to Develop Anti-Cancer Drugs Utilizing Artificial Intelligence	23-10-26	CI
HC Wainwright Adjusts Can-Fite Biopharma Price Target to $18 From $34, Maintains Buy Rating	23-10-24	MT
Can-Fite BioPharma Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31	CI
Can-Fite Enters Rare Genetic Disease Field Based on Impactful Findings of A Fondazione Telethon and Naples University Researcher Showing Piclidenoson Is Efficacious in Treating Lowe Syndrome	23-08-24	CI
Can-Fite Biopharma Ltd. Submits Pediatric Plan to U.S. Food and Drug Administration to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis	23-08-18	CI

Chart Can-Fite BioPharma Ltd.

Duration

Period

More charts

Company Profile

Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

Sector

Pharmaceuticals

Calendar

2024-05-29 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	-3.70%	88.91B
SAMSUNG BIOLOGICS CO.,LTD.	+4.08%	41.25B
BIOGEN INC.	-15.09%	31.99B
UCB	+53.68%	24.73B
BIOMARIN PHARMACEUTICAL INC.	-15.13%	15.54B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-8.63%	12.05B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-40.39%	12.07B
SWEDISH ORPHAN BIOVITRUM AB	+6.22%	8.84B
INNOVENT BIOLOGICS, INC.	-6.20%	8.3B

Biopharmaceuticals